A study of Enfortumab Vedotin for urothelial cancer
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Disease Types: Bladder
Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
For more information:
https://clinicaltrials.gov/ct2/show/NCT03288545?term=NCT03288545&draw=2&rank=1